IDEXX Laboratories (IDXX) Competitors

IDEXX Laboratories logo
$689.65 -8.82 (-1.26%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$698.15 +8.50 (+1.23%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDXX vs. NVST, ABT, ISRG, MDT, and SYK

Should you buy IDEXX Laboratories stock or one of its competitors? IDEXX Laboratories's main competitors and comparable companies include Envista (NVST), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Medtronic (MDT), and Stryker (SYK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does IDEXX Laboratories compare to Envista?

Envista (NYSE:NVST) and IDEXX Laboratories (NASDAQ:IDXX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, IDEXX Laboratories had 2 more articles in the media than Envista. MarketBeat recorded 2 mentions for IDEXX Laboratories and 0 mentions for Envista. IDEXX Laboratories' average media sentiment score of 0.89 beat Envista's score of 0.53 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company Overall Sentiment
Envista Positive
IDEXX Laboratories Positive

87.8% of IDEXX Laboratories shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Envista currently has a consensus target price of $29.00, indicating a potential upside of 24.69%. IDEXX Laboratories has a consensus target price of $717.27, indicating a potential upside of 4.01%. Given Envista's higher possible upside, research analysts plainly believe Envista is more favorable than IDEXX Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Envista
0 Sell rating(s)
11 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.35
IDEXX Laboratories
0 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.54

IDEXX Laboratories has a net margin of 25.36% compared to Envista's net margin of 22.01%. IDEXX Laboratories' return on equity of 71.04% beat Envista's return on equity.

Company Net Margins Return on Equity Return on Assets
Envista22.01% 8.26% 4.54%
IDEXX Laboratories 25.36%71.04%33.99%

Envista has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

IDEXX Laboratories has higher revenue and earnings than Envista. Envista is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.72B1.37$47M$3.876.01
IDEXX Laboratories$4.30B12.63$1.06B$14.8346.50

Summary

IDEXX Laboratories beats Envista on 14 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

IDEXX Laboratories has a net margin of 25.36% compared to Abbott Laboratories' net margin of 9.75%. IDEXX Laboratories' return on equity of 71.04% beat Abbott Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Abbott Laboratories9.75% 18.04% 9.09%
IDEXX Laboratories 25.36%71.04%33.99%

Abbott Laboratories has higher revenue and earnings than IDEXX Laboratories. Abbott Laboratories is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$44.33B4.06$6.52B$2.6838.82
IDEXX Laboratories$4.30B12.63$1.06B$14.8346.50

Abbott Laboratories has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

Abbott Laboratories currently has a consensus price target of $119.04, indicating a potential upside of 14.43%. IDEXX Laboratories has a consensus price target of $717.27, indicating a potential upside of 4.01%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, equities analysts plainly believe Abbott Laboratories is more favorable than IDEXX Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abbott Laboratories
0 Sell rating(s)
4 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.89
IDEXX Laboratories
0 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.54

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Abbott Laboratories had 24 more articles in the media than IDEXX Laboratories. MarketBeat recorded 26 mentions for Abbott Laboratories and 2 mentions for IDEXX Laboratories. Abbott Laboratories' average media sentiment score of 1.21 beat IDEXX Laboratories' score of 0.89 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abbott Laboratories
16 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEXX Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

IDEXX Laboratories beats Abbott Laboratories on 9 of the 17 factors compared between the two stocks.

How does IDEXX Laboratories compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Intuitive Surgical has higher revenue and earnings than IDEXX Laboratories. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$10.06B14.03$2.86B$8.2749.24
IDEXX Laboratories$4.30B12.63$1.06B$14.8346.50

In the previous week, Intuitive Surgical had 23 more articles in the media than IDEXX Laboratories. MarketBeat recorded 25 mentions for Intuitive Surgical and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 0.89 beat Intuitive Surgical's score of 0.80 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intuitive Surgical
15 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEXX Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Intuitive Surgical has a net margin of 25.54% compared to IDEXX Laboratories' net margin of 25.36%. IDEXX Laboratories' return on equity of 71.04% beat Intuitive Surgical's return on equity.

Company Net Margins Return on Equity Return on Assets
Intuitive Surgical25.54% 18.17% 15.73%
IDEXX Laboratories 25.36%71.04%33.99%

Intuitive Surgical currently has a consensus price target of $495.90, indicating a potential upside of 21.77%. IDEXX Laboratories has a consensus price target of $717.27, indicating a potential upside of 4.01%. Given Intuitive Surgical's stronger consensus rating and higher possible upside, equities analysts plainly believe Intuitive Surgical is more favorable than IDEXX Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intuitive Surgical
1 Sell rating(s)
5 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.80
IDEXX Laboratories
0 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.54

Intuitive Surgical has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Summary

Intuitive Surgical beats IDEXX Laboratories on 9 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Medtronic?

Medtronic (NYSE:MDT) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Medtronic has higher revenue and earnings than IDEXX Laboratories. Medtronic is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$36.36B3.54$4.80B$4.0624.77
IDEXX Laboratories$4.30B12.63$1.06B$14.8346.50

Medtronic has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

82.1% of Medtronic shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 0.3% of Medtronic shares are held by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Medtronic presently has a consensus target price of $104.17, indicating a potential upside of 3.58%. IDEXX Laboratories has a consensus target price of $717.27, indicating a potential upside of 4.01%. Given IDEXX Laboratories' higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than Medtronic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medtronic
1 Sell rating(s)
8 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.63
IDEXX Laboratories
0 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.54

In the previous week, Medtronic had 32 more articles in the media than IDEXX Laboratories. MarketBeat recorded 34 mentions for Medtronic and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 0.89 beat Medtronic's score of 0.61 indicating that IDEXX Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medtronic
14 Very Positive mention(s)
8 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEXX Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

IDEXX Laboratories has a net margin of 25.36% compared to Medtronic's net margin of 13.93%. IDEXX Laboratories' return on equity of 71.04% beat Medtronic's return on equity.

Company Net Margins Return on Equity Return on Assets
Medtronic13.93% 14.78% 7.97%
IDEXX Laboratories 25.36%71.04%33.99%

Summary

IDEXX Laboratories beats Medtronic on 11 of the 16 factors compared between the two stocks.

How does IDEXX Laboratories compare to Stryker?

IDEXX Laboratories (NASDAQ:IDXX) and Stryker (NYSE:SYK) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

IDEXX Laboratories has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Stryker had 16 more articles in the media than IDEXX Laboratories. MarketBeat recorded 18 mentions for Stryker and 2 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 0.89 beat Stryker's score of 0.59 indicating that IDEXX Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IDEXX Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stryker
6 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by insiders. Comparatively, 4.6% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

IDEXX Laboratories presently has a consensus price target of $717.27, indicating a potential upside of 4.01%. Stryker has a consensus price target of $343.77, indicating a potential upside of 9.77%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than IDEXX Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories
0 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.54
Stryker
0 Sell rating(s)
7 Hold rating(s)
21 Buy rating(s)
0 Strong Buy rating(s)
2.75

IDEXX Laboratories has a net margin of 25.36% compared to Stryker's net margin of 13.78%. IDEXX Laboratories' return on equity of 71.04% beat Stryker's return on equity.

Company Net Margins Return on Equity Return on Assets
IDEXX Laboratories25.36% 71.04% 33.99%
Stryker 13.78%23.74%11.64%

Stryker has higher revenue and earnings than IDEXX Laboratories. Stryker is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$4.30B12.63$1.06B$14.8346.50
Stryker$25.12B4.75$3.25B$9.3933.35

Summary

IDEXX Laboratories beats Stryker on 9 of the 16 factors compared between the two stocks.

Get IDEXX Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDXX vs. The Competition

MetricIDEXX LaboratoriesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$55.03B$5.92B$7.57B$11.70B
Dividend YieldN/A1.69%2.48%4.65%
P/E Ratio47.1938.8133.9628.21
Price / Sales12.635.308.375.48
Price / Cash46.3023.4220.7221.66
Price / Book29.064.154.433.65
Net Income$1.06B$143.14M$3.51B$394.00M
7 Day Performance-2.07%-4.70%-5.52%-5.64%
1 Month Performance23.61%-6.70%-8.70%-9.48%
1 Year Performance0.04%-1.04%-1.43%-6.81%

IDEXX Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDXX
IDEXX Laboratories
2.1515 of 5 stars
$689.65
-1.3%
$717.27
+4.0%
-1.1%$55.03B$4.30B47.1911,000
NVST
Envista
3.6554 of 5 stars
$25.98
+3.2%
$29.00
+11.6%
+22.7%$4.37B$2.72B6.7112,000
ABT
Abbott Laboratories
4.4033 of 5 stars
$110.41
+0.4%
$118.32
+7.2%
-17.6%$199.88B$44.33B21.47115,000
ISRG
Intuitive Surgical
4.0959 of 5 stars
$460.56
+1.7%
$493.54
+7.2%
-27.9%$167.12B$10.06B54.0517,021
MDT
Medtronic
4.4214 of 5 stars
$102.73
+0.9%
$102.88
+0.1%
+0.5%$134.26B$36.36B18.3595,000

Related Companies and Tools


This page (NASDAQ:IDXX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners